Please login to the form below

mantle cell lymphoma

This page shows the latest mantle cell lymphoma news and features for those working in and with pharma, biotech and healthcare.

Imbruvica gains expanded use in Europe

It is also approved for use in mantle cell lymphoma (MCL) for the treatment of adult patients who have relapsed or refractory MCL. ... B-cell lymphoma.

Latest news

AZ’s Calquence threatens Imbruvica with new leukaemia data

Calquence is currently a minnow in comparison, making $62m last year as a treatment for mantle cell lymphoma (MCL), its first and only approved indication at the moment. ... AZ has a host of studies testing its BTK inhibitor in diseases such as multiple
New data backs Merck’s segue into MS with BTK inhibitor

drug, which is already used for relapsed or refractory mantle cell lymphoma (MCL).
Cancer drugs and China sustain AZ’s return to growth

The star in oncology for AZ is non-small cell lung cancer (NSCLC) therapy Tagrisso (osimertinib), which grew 95% to $1.86bn last year, thanks to a move up the treatment ... cell lymphoma, along with new MEK inhibitor selumetinib in neurofibromatosis type
Celgene’s Revlimid gets a win in late-stage lymphoma

Celgene is planning to file for approval of Revlimid in the new indication early next year, adding to its current uses in multiple myeloma, mantle cell lymphoma, and anaemia associated with ... An earlier read-out in diffuse large B-cell lymphoma (DLBCL)
Another R&D flop for Incyte, but Jakafi keeps delivering

Meanwhile, Incyte was quick to point out that the failure of PI3K delta inhibitor INCB50465 in a form of NHL called diffuse large B cell lymphoma (DLBCL) does not affect phase ... II testing of the drug in other indications, including follicular lymphoma,

More from news
Approximately 2 fully matching, plus 58 partially matching documents found.

Latest Intelligence

AstraZeneca: building a new ‘open innovation’ pharma company

AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director – UK Office: Excellent salary and benefits

Account Director, Healthcare Communications: Salary TBC

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

A uniquely English genomic medicine service: The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....